{
    "clinical_study": {
        "@rank": "20185", 
        "acronym": "GRAMAL", 
        "arm_group": [
            {
                "arm_group_label": "DEPIGOID phleum", 
                "arm_group_type": "Active Comparator", 
                "description": "The active treatment arm receive active phleum pollen immunotherapy (Depigoid 100% phleum). Depigmented and polymerized allergen extract of Phleum pollen for subcutaneous injection."
            }, 
            {
                "arm_group_label": "DEPIGOID Placebo & DEPIGOID Phleum", 
                "arm_group_type": "Placebo Comparator", 
                "description": "This arm receive DEPIGOID Placebo during the first year, and DEPIGOID Phleum during the second year of study.\nDEPIGOID Placebo contains the same composition as in the active DEPIGOID Phleum with the only difference being the exclusion of the phleum pollen allergen extract."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is evaluate the efficacy of a depigmented grass extract in the\n      treatment of local allergic rhinitis."
        }, 
        "brief_title": "Efficacy of a Depigmented Extract of Phleum in Local Allergic Rhinitis", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Allergic Rhinitis", 
        "condition_browse": {
            "mesh_term": "Rhinitis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Local allergic rhinitis with sensitization to grass pollen\n\n          -  Skin prick test and serum specific IgE negative to grass pollen.\n\n          -  Positive Nasal allergen provocation test (NAPT) to grass pollen and/or positive nasal\n             specific IgE to grass pollen.\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Immunological diseases\n\n          -  Heart diseases that limit the use of adrenaline. For example, severe hypertension or\n             treatment with beta-blockers.\n\n          -  Treatment with beta-blockers\n\n          -  Severe psychological disorders\n\n          -  Severe atopic dermatitis\n\n          -  FEV1 < 70% of reference value after treatment\n\n          -  Hypersensitivity or intolerance to excipients and / or medication trial.\n\n          -  Failure to adequately perform diagnostic tests or treatment.\n\n          -  Sensitization to other allergens (perennial or seasonal) with clinical relevance for\n             the subject and that may interfere in the evaluation of the response.\n\n          -  Immunotherapy in the 5 years prior to their inclusion in the study.\n\n          -  Pregnant women or at risk of pregnancy and lactating women."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02126111", 
            "org_study_id": "MBG6043179"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "DEPIGOID phleum", 
                    "DEPIGOID Placebo & DEPIGOID Phleum"
                ], 
                "description": "Subcutaneous Immunotherapy with modified extract of Phleum pollen.", 
                "intervention_name": "DEPIGOID phleum", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "DEPIGOID Placebo & DEPIGOID Phleum", 
                "description": "Placebo for subcutaneous administration", 
                "intervention_name": "DEPIGOID Placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 27, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Infanta Leonor"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Malaga", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Regional Universitario Carlos Haya"
                }
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy of a Depigmented Extract of Phleum in the Treatment of Local Allergic Rhinitis", 
        "overall_official": {
            "affiliation": "Hospital Regional Universitario, M\u00e1laga, Spain", 
            "last_name": "Miguel Blanca, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Patients were provided a diary to score the severity of their symptoms and the use of rescue medication during 4 weeks in two consecutive springs.\nNasal symptoms of rhinorrhea, nasal congestion, sneezing, nasal itching, and ocular symptoms were recorded using a 4-point categorical scale from 0 to 3 (0: no symptoms, 1:mild, 2:moderate; 3:severe).\nThe use of rescue medication was recorded in the patient diary according to the following score:\nOral antihistamines (1 tablet = 1 point); intranasal corticosteroids (400mcg/day of beclometasone or equivalent = 1.4 points); and ocular antihistamines (1 dose = 1 point).", 
            "measure": "Symptoms and medication scores comparison between active and placebo group", 
            "safety_issue": "No", 
            "time_frame": "two years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02126111"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Plaza del Hospital Civil", 
            "investigator_full_name": "Miguel Blanca Gomez", 
            "investigator_title": "Director Allergy Unit", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The response to NAPT-Phl with increasing concentrations of phleum pratense (0.001-0.01-0.05-0.1 mcg/ml) will be evaluated by nasal symptoms and acoustic rhinometry.", 
                "measure": "Response to nasal allergen provocation test with phleum (NAPT-Phl)", 
                "safety_issue": "No", 
                "time_frame": "two years"
            }, 
            {
                "description": "Evaluation of SPT wheal size.", 
                "measure": "Skin prick-test (SPT) with phleum.", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "IDT wheal and erythema size.", 
                "measure": "Intradermal test (IDT) with phleum", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "FEV1", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Quality of life questionnaire RQLQ", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Flow cytometry study for determination of IFN-gamma, IL-13, IL-5, IL-8, IL-10, IL-12, IL-2 in peripheral blood and nasal lavage", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Determination of tryptase, eosinophil cationic protein, IgG, IgG4, specific IgE to grass (Phl p1, Phl p5, Phl p7, Phl p12) in peripheral blood and nasal lavage.", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Heart rate", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Blood pressure", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Plaza del Hospital Civil", 
        "sponsors": {
            "collaborator": {
                "agency": "Laboratorios Leti, S.L.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Plaza del Hospital Civil", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}